DK0864646T3 - Fremgangsmåde til inaktivering af kappevira - Google Patents
Fremgangsmåde til inaktivering af kappeviraInfo
- Publication number
- DK0864646T3 DK0864646T3 DK98890036T DK98890036T DK0864646T3 DK 0864646 T3 DK0864646 T3 DK 0864646T3 DK 98890036 T DK98890036 T DK 98890036T DK 98890036 T DK98890036 T DK 98890036T DK 0864646 T3 DK0864646 T3 DK 0864646T3
- Authority
- DK
- Denmark
- Prior art keywords
- viruses
- virus
- intact
- structural integrity
- inactivating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16761—Methods of inactivation or attenuation
- C12N2710/16763—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16061—Methods of inactivation or attenuation
- C12N2740/16063—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16061—Methods of inactivation or attenuation
- C12N2760/16063—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0029997A AT405939B (de) | 1997-02-24 | 1997-02-24 | Verfahren zur inaktivierung von lipidumhüllten viren |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0864646T3 true DK0864646T3 (da) | 2006-11-20 |
Family
ID=3486870
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05112299.2T DK1637593T3 (da) | 1997-02-24 | 1998-02-12 | Fremgangsmåde til inaktivering af lipidomhyllede vira |
DK98890036T DK0864646T3 (da) | 1997-02-24 | 1998-02-12 | Fremgangsmåde til inaktivering af kappevira |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05112299.2T DK1637593T3 (da) | 1997-02-24 | 1998-02-12 | Fremgangsmåde til inaktivering af lipidomhyllede vira |
Country Status (7)
Country | Link |
---|---|
US (1) | US6136321A (da) |
EP (2) | EP1637593B1 (da) |
JP (1) | JPH10234362A (da) |
AT (3) | AT405939B (da) |
DE (2) | DE59813677D1 (da) |
DK (2) | DK1637593T3 (da) |
ES (2) | ES2270501T3 (da) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2236378C (en) | 1995-11-01 | 2011-01-25 | Dnavec Research Inc. | Recombinant sendai virus |
JP4540795B2 (ja) * | 2000-03-10 | 2010-09-08 | 一般財団法人阪大微生物病研究会 | 生ワクチンの細胞性免疫活性を不活化ワクチンにも起こさせる方法、及びこれより得られる混合ワクチン |
US7407662B2 (en) * | 2000-06-29 | 2008-08-05 | Lipid Sciences, Inc. | Modified viral particles with immunogenic properties and reduced lipid content |
AU2008201523B2 (en) * | 2000-06-29 | 2011-07-28 | Eli Lilly And Company | Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases |
AU2004264842B2 (en) * | 2000-06-29 | 2008-01-10 | Eli Lilly And Company | Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases |
US20090017069A1 (en) | 2000-06-29 | 2009-01-15 | Lipid Sciences, Inc. | SARS Vaccine Compositions and Methods of Making and Using Them |
US7407663B2 (en) * | 2000-06-29 | 2008-08-05 | Lipid Sciences, Inc. | Modified immunodeficiency virus particles |
AUPQ846900A0 (en) * | 2000-06-29 | 2000-07-27 | Aruba International Pty Ltd | A vaccine |
BR0114392A (pt) * | 2000-10-02 | 2003-09-02 | Glaxosmithkline Biolog Sa | Formulação de vacina, método para produzir uma formulação de vacina, uso de uma preparação de vacina contra rsv dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por rsv |
DK1326963T3 (da) | 2000-10-17 | 2008-08-25 | Zeptometrix Corp | Mikroorganismer, som er gjort ikke-patogene |
US6524586B2 (en) | 2001-05-18 | 2003-02-25 | Albany Medical College | Enhancement of oligomeric viral immunogenicity |
WO2003000372A2 (en) * | 2001-06-25 | 2003-01-03 | Lipid Sciences, Inc. | Systems and methods using multiple solvents for the removal of lipids from fluids |
US6991727B2 (en) * | 2001-06-25 | 2006-01-31 | Lipid Sciences, Inc. | Hollow fiber contactor systems for removal of lipids from fluids |
US20030127386A1 (en) * | 2001-06-25 | 2003-07-10 | Bomberger David C. | Hollow fiber contactor systems for removal of lipids from fluids |
US7393826B2 (en) | 2003-07-03 | 2008-07-01 | Lipid Sciences, Inc. | Methods and apparatus for creating particle derivatives of HDL with reduced lipid content |
CA2531227A1 (en) | 2003-07-03 | 2005-02-10 | Lipid Sciences Inc. | Methods and apparatus for creating particle derivatives of hdl with reduced lipid content |
US20090214590A1 (en) * | 2005-07-08 | 2009-08-27 | Wayne State University | Virus Vaccines Comprising Envelope-Bound Immunomodulatory Proteins and Methods of Use Thereof |
US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
NZ568210A (en) * | 2005-11-04 | 2012-12-21 | Novartis Vaccines & Diagnostic | Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines |
HUE051122T2 (hu) | 2005-11-04 | 2021-03-01 | Seqirus Uk Ltd | Sejttenyészetben növesztett influenzavírusból elõállított nemvirion anti-géneket tartalmazó adjuvált vakcinák |
CN101790381B (zh) * | 2007-08-28 | 2014-08-27 | 巴克斯特国际公司 | 生产病毒疫苗的方法 |
EP2396032B1 (en) | 2009-02-10 | 2016-09-28 | Seqirus UK Limited | Influenza vaccines with reduced amounts of squalene |
US20110110975A1 (en) * | 2009-11-06 | 2011-05-12 | Streck, Inc. | Inactivated virus compositions and methods of preparing such compositions |
EP2704740B1 (en) | 2011-05-04 | 2016-10-05 | Streck, Inc. | Inactivated swine flu virus and methods of preparing it |
KR102238133B1 (ko) | 2013-11-15 | 2021-04-09 | 제넨테크, 인크. | 환경-친화적 세제를 사용한 바이러스 불활성화 방법 |
MX2020004543A (es) * | 2017-11-03 | 2020-09-18 | Takeda Vaccines Inc | Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan. |
WO2019104237A1 (en) | 2017-11-22 | 2019-05-31 | Hdl Therapeutics, Inc. | Systems and methods for priming fluid circuits of a plasma processing system |
MX2020004633A (es) * | 2017-11-30 | 2020-09-28 | Takeda Vaccines Inc | Metodo para inactivar el virus de zika y metodos relacionados. |
WO2019133358A2 (en) | 2017-12-28 | 2019-07-04 | Hdl Therapeutics, Inc. | Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma |
MX2022006987A (es) * | 2019-12-12 | 2022-07-13 | Lilly Co Eli | Metodos para la inactivacion viral mediante detergentes compatibles con el medioambiente. |
CN115996940A (zh) * | 2020-07-01 | 2023-04-21 | 免疫医疗有限责任公司 | 用于纯化生物治疗剂的洗涤剂和方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4164565A (en) | 1975-03-14 | 1979-08-14 | New York Blood Center, Inc. | Vaccine for active immunization containing hepatitis B surface antigen and associated antigen |
DE3014189A1 (de) * | 1980-04-14 | 1981-10-15 | Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg | Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren |
US4314997A (en) | 1980-10-06 | 1982-02-09 | Edward Shanbrom | Purification of plasma protein products |
US4673733A (en) * | 1985-04-11 | 1987-06-16 | Sudhish Chandra | Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents |
DE3704550A1 (de) * | 1987-02-13 | 1988-08-25 | Behringwerke Ag | Verfahren zur inaktivierung huellhaltiger viren in mittels einer zelle in vitro hergestellten protein-praeparationen |
CZ288048B6 (cs) * | 1991-07-25 | 2001-04-11 | Idec Pharmaceuticals Corporation | Farmaceutická kompozice k indukci cytotoxické odpovědi T-lymfocytů |
DE4211108A1 (de) * | 1992-04-03 | 1993-10-07 | Boehringer Mannheim Gmbh | Viruslösung zum Einsatz bei Immunoassays |
GB9513261D0 (en) * | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
-
1997
- 1997-02-24 AT AT0029997A patent/AT405939B/de not_active IP Right Cessation
-
1998
- 1998-02-10 US US09/021,146 patent/US6136321A/en not_active Expired - Lifetime
- 1998-02-12 DE DE59813677T patent/DE59813677D1/de not_active Expired - Lifetime
- 1998-02-12 AT AT05112299T patent/ATE478138T1/de active
- 1998-02-12 DE DE59814464T patent/DE59814464D1/de not_active Expired - Lifetime
- 1998-02-12 ES ES98890036T patent/ES2270501T3/es not_active Expired - Lifetime
- 1998-02-12 EP EP05112299A patent/EP1637593B1/de not_active Expired - Lifetime
- 1998-02-12 DK DK05112299.2T patent/DK1637593T3/da active
- 1998-02-12 DK DK98890036T patent/DK0864646T3/da active
- 1998-02-12 AT AT98890036T patent/ATE335810T1/de active
- 1998-02-12 ES ES05112299T patent/ES2350109T3/es not_active Expired - Lifetime
- 1998-02-12 EP EP98890036A patent/EP0864646B1/de not_active Expired - Lifetime
- 1998-02-20 JP JP10038604A patent/JPH10234362A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ATE478138T1 (de) | 2010-09-15 |
EP1637593B1 (de) | 2010-08-18 |
JPH10234362A (ja) | 1998-09-08 |
AT405939B (de) | 1999-12-27 |
DE59814464D1 (de) | 2010-09-30 |
DE59813677D1 (de) | 2006-09-21 |
ES2270501T3 (es) | 2007-04-01 |
EP0864646B1 (de) | 2006-08-09 |
US6136321A (en) | 2000-10-24 |
ES2350109T3 (es) | 2011-01-18 |
EP1637593A1 (de) | 2006-03-22 |
EP0864646A3 (de) | 2002-05-15 |
EP0864646A2 (de) | 1998-09-16 |
DK1637593T3 (da) | 2010-11-22 |
ATE335810T1 (de) | 2006-09-15 |
ATA29997A (de) | 1999-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0864646T3 (da) | Fremgangsmåde til inaktivering af kappevira | |
ES511668A0 (es) | "metodo para inactivar los virus infecciosos contenidos en una composicion enzimatica hemocoagulante". | |
EA199700272A1 (ru) | Вакцины, содержащие сапонин и стерин | |
DE59410380D1 (de) | Endosomolytisch wirksame partikel | |
HK1009980A1 (en) | Method for selective inactivation of viral replication | |
BR0014282A (pt) | Vacinas | |
ES2191663T3 (es) | Virus recombinante de la viruela porcina. | |
AU6790087A (en) | Modification of plant viruses or their effects | |
EA200000528A1 (ru) | Способ получения вакцин для предупреждения патогенных эффектов, связанных с ретровирусной инфекцией | |
DK0512011T3 (da) | Blodfaktorer fremstillet ved rekombinant DNA-teknologi, fremgangsmåde til ekspression af blodfaktorerne samt vacciniavirusrekombinanter anvendt ved fremgangsmåden | |
CA2153780A1 (en) | Method of inhibiting viral reproduction | |
ES2058418T3 (es) | Preparacion farmaceutica contra enfermedades viricas que comprende un extracto de higado. | |
ATE365206T1 (de) | Verfahren zur entwicklung von einem hiv impfstoff | |
DK0480949T3 (da) | Fremstilling af virus og oprensning af virale kappeproteiner til vaccineanvendelse | |
NO971495L (no) | Svekkede virus og fremgangsmåte til deres fremstilling | |
AR001399A1 (es) | Una composición acondicionadora del cabello. | |
DK8789D0 (da) | Fremgangsmaade til fremstilling af modificerede, staerkt afsvaekkede rna-virusstammer samt vaccine og dens anvendelse | |
ES2170845T3 (es) | Procedimiento para la inactivacion de virus en proteinas. | |
PT88430A (pt) | Vecteur d'expression des proteines du virus hiv-2 un agent causal du sida culture cellulaire infectee ou transformee par ce vecteur procede de preparation de proteines et d'un vaccin et anticorps obtenus | |
ES550089A0 (es) | Procedimiento para producir una vacuna coadyuvada que contiene un antigeno seleccionado de proteinas, bacterias y virus. | |
BR0009221A (pt) | Vetores virais de inseto e usos dos mesmos | |
FI893346A (fi) | Icke-reverterande rna-virus. | |
DE69422980T2 (de) | Extrakte von Piliostigma thonningii, deren Verwendung und diese enthaltende Zubereitungen | |
MacArthur | Viral Sex: The Nature of AIDS. | |
DE59410140D1 (de) | Rinderovarzellinie (FROv) zur Virusvermehrung |